Cochrane · systematic review · CD007277
Abatacept for rheumatoid arthritis
Maxwell, L, Singh, JA · Cochrane Database of Systematic Reviews · 2009 · Cochrane Library
MusculoskeletalAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 6 · 85.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Abatacept (2 and 10mg/kg) + DMARDs/biologic versus placebo + DMARDs/biologic for rheumatoid arthritis
Population: patients with rheumatoid arthritis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ACR 50% improvement Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic | RR 2.21 [1.73, 2.82] | 3 studies · 993 participants | Moderate Downgraded: risk of bias |
Pain measured at end of study on a 100 mm visual analog scale. Scale from: 0 (better) to 100 (worse). Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic | no estimate extracted | 1 study · 1425 participants | Moderate |
Improvement in physical function (HAQ: greater than 0.3 increase from baseline, 0‐3 scale) Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic | RR 1.62 [1.35, 1.95] | 1 study · 638 participants | Moderate |
Achievement of low disease activity state (DAS 28 less than 3.2, scale 0‐10) Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic | RR 4.33 [2.84, 6.59] | 1 study · 638 participants | Moderate |
Total serious adverse events Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic | RR 1.05 [0.87, 1.28] | 6 studies · 3151 participants | Moderate Downgraded: risk of bias |
Change in radiographic progression measured by Genant‐modifed Sharp erosion score (increase in score means more joint damage). Scale from: 0 to 145. Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic | no estimate extracted | 1 study · 586 participants | Moderate |
Long‐term serious adverse events Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic | no estimate extracted | 2 studies · 950 participants | Low |